Literature DB >> 4723255

Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

G H Evans, D G Shand.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4723255     DOI: 10.1002/cpt1973144part1487

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  51 in total

1.  Quantitation of hepatic and pulmonary first-pass effects and its implications in pharmacokinetic study. I. Pharmacokinetics of chloroform in man.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1975-06

2.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

3.  [Drug therapy of tachyarrhythmias (author's transl)].

Authors:  K Theisen
Journal:  Klin Wochenschr       Date:  1978-02-15

4.  Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

Authors:  G Alván; M Lind; B Mellström; C von Bahr
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

5.  Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.

Authors:  D F Schoors; I Vercruysse; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

6.  An escape phenomenon from water and sodium retention induced by propranolol in rats.

Authors:  J M López-Novoa; S Casado; L Hernando
Journal:  Experientia       Date:  1978-02-15

Review 7.  Propranolol disposition in chronic liver disease: a physiological approach.

Authors:  R A Branch; D G Shand
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Propranolol does not alter flutoprazepam kinetics and metabolism in the rat.

Authors:  I Conti; S Sarati; S Caccia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

9.  Direct measurement of propranolol bioavailability during accumulation to steady-state.

Authors:  A J Wood; K Carr; R E Vestal; S Belcher; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.